These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 543899)

  • 1. Pharmacokinetics of azlocillin in children with cystic fibrosis.
    Bergan T; Michalsen H
    Arzneimittelforschung; 1979; 29(12a):1955-7. PubMed ID: 543899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of high-dose azlocillin sodium in patients with cystic fibrosis.
    Woolf RA; Koup JR; Smith AL; Hilman BC; Goldmann D; Williams-Warren J
    Clin Pharm; 1985; 4(6):664-9. PubMed ID: 4075734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetics of Azlocillin in premature and newborn infants (author's transl)].
    Heimann G; von Heereman B; Gladtke E
    Arzneimittelforschung; 1979; 29(12a):1949-51. PubMed ID: 543897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of azlocillin in children with and without cystic fibrosis treated for infectious diseases.
    Michalsen H; Bergan T
    Methods Find Exp Clin Pharmacol; 1986 Dec; 8(12):727-9. PubMed ID: 3807473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with azlocillin in complicated urinary tract infections.
    Alfthan O; Renkonen OV; Ohlsson H
    Arzneimittelforschung; 1979; 29(12a):1979-81. PubMed ID: 543906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of acylureidopenicillin pharmacokinetics.
    Bergan T
    Scand J Infect Dis Suppl; 1981; 29():33-48. PubMed ID: 7031864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [On the excretion of azlocillin with bronchial secretion in children (author's transl)].
    Weingärtner L; Sitka U; Patsch R; Richter I; Thiemann HH
    Arzneimittelforschung; 1979; 29(12a):1952-4. PubMed ID: 543898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Degradation of Azlocillin and Mezlocillin / I. Behaviour in biological material and buffer (author's transl)].
    Gundert-Remy U; Weber E
    Arzneimittelforschung; 1981; 31(12):2041-4. PubMed ID: 6460506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of azlocillin in healthy subjects.
    Leroy A; Humbert G; Fillastre JP
    Scand J Infect Dis Suppl; 1981; 29():49-54. PubMed ID: 6947405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudomonas infections of the lung treated with azlocillin. Microbiology, pharmacokinetics, clinic.
    Daikos GK; Giamarellou H; Hadjipolydorou K; Kanellakopoulou K
    Arzneimittelforschung; 1979; 29(12a):1976-8. PubMed ID: 120747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azlocillin pharmacokinetics in patients with cystic fibrosis.
    Bosso JA; Saxon BA; Herbst JJ; Matsen JM
    Antimicrob Agents Chemother; 1984 May; 25(5):630-2. PubMed ID: 6732230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetics after discontinuous intravenous administration of azlocillin].
    Naber K; Adam D
    Arzneimittelforschung; 1983; 33(3):429-32. PubMed ID: 6683518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mezlocillin concentrations in human bone tissue].
    Vent J
    Arzneimittelforschung; 1979; 29(12a):1969-71. PubMed ID: 543904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between the pharmacokinetic properties of mezlocillin when given intravenously as a bolus injection or as an infusion.
    Ohlsson H; Bergan T
    Arzneimittelforschung; 1979; 29(12a):1958-9. PubMed ID: 543900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Azlocillin in the treatment of pulmonary infections in patients with cystic fibrosis: plasma concentrations and therapeutic indications].
    Rosselli P; Marianelli L; Valenza T; Bartolozzi G
    Pediatr Med Chir; 1989; 11(4):389-91. PubMed ID: 2694104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elimination kinetics of mezlocillin in normal and impaired renal function including the effects of dialysis.
    Kosmidis J; Doundoulaki P; Stathakis C; Zerefos N; Bounia A; Daikos GK
    Arzneimittelforschung; 1979; 29(12a):1960-2. PubMed ID: 543901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of the pharmacokinetics and dose dependency of azlocillin in normal subjects and patients with renal insufficiency.
    Bergan T
    J Antimicrob Chemother; 1983 May; 11 Suppl B():101-14. PubMed ID: 6352598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of infusion rate on pharmacokinetic parameters of azlocillin and mezlocillin].
    Haen E; Remien J; Richter E; Frank U; Adam D
    Arzneimittelforschung; 1985; 35(5):864-8. PubMed ID: 4026911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple-dose pharmacokinetics of piperacillin and azlocillin in 12 healthy volunteers.
    Tartaglione TA; Nye L; Vishniavsky N; Poynor W; Polk RE
    Clin Pharm; 1986 Nov; 5(11):911-6. PubMed ID: 3780161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic evaluation of cefsulodin in children with and without cystic fibrosis treated for infectious diseases.
    Michalsen H; Bergan T; Solberg R
    Methods Find Exp Clin Pharmacol; 1986 Nov; 8(11):685-7. PubMed ID: 3807469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.